Highlight 1 in breast cancer
Today marks the start of the ASCO 2023 congress, with the first oral abstract session focusing on local, regional, and adjuvant treatment for breast cancer. MediMix sought the expertise of Prof Patrick Neven from the University Hospital Gasthuisberg, Leuven, who provided a concise ten-minute summary of the presented data.
During the session, Prof Neven highlighted key findings from the phase III NATALEE trial, which investigated the use of ribociclib and endocrine therapy as adjuvant treatment for patients with HR+/HER2- early breast cancer. He also presented a subgroup analysis from the monarchE study, which offers guidance on managing older patients receiving adjuvant abemaciclib. In addition, a meta-analysis evaluated the significance of ovarian ablation or suppression in young pre-menopausal women. Finally, Prof Neven discussed the potential of biomarkers for breast cancer.
With the educational support of:
